BioLineRx Enrols First Patient for Neuropathic Drug Phase I Study

The study will evaluate the safety, tolerability and pharmacokinetics of single or multiple doses of BL-1021 in healthy volunteers.

BioLineRx, a clinical stage biopharmaceutical development company, has enrolled the first patient in a Phase I study of BL-1021, an oral drug to treat neuropathic pain.

The first-in-human, single-site, double-blind and placebo-controlled study will evaluate the safety, tolerability and pharmacokinetics of single or multiple doses of BL-1021 in healthy volunteers.

The study, carried out by professor Yoseph Caraco at the Hadassah Clinical Research Center, is expected to enrol up to 56 people.

Preclinical studies have shown that BL-1021 has a lowered propensity for sedation, no cardiac toxicity and improved efficacy compared with other anti-pain medications.